Biosig Technologies, Common Stock Performance
| BSGM Stock | USD 1.79 0.12 6.28% |
BioSig Technologies, holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.53, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BioSig Technologies, are expected to decrease at a much lower rate. During the bear market, BioSig Technologies, is likely to outperform the market. Use BioSig Technologies, sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on BioSig Technologies,.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in BioSig Technologies, Common are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain technical and fundamental indicators, BioSig Technologies, displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 357 K |
BioSig |
BioSig Technologies, Relative Risk vs. Return Landscape
If you would invest 44.00 in BioSig Technologies, Common on September 1, 2024 and sell it today you would earn a total of 135.00 from holding BioSig Technologies, Common or generate 306.82% return on investment over 90 days. BioSig Technologies, Common is currently generating 3.0291% in daily expected returns and assumes 13.4256% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioSig, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioSig Technologies, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioSig Technologies,'s investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as BioSig Technologies, Common, and traders can use it to determine the average amount a BioSig Technologies,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2256
| Best Portfolio | Best Equity | |||
| Good Returns | BSGM | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.43 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.03 actual daily | 60 60% of assets have lower returns |
Risk-Adjusted Return
| 0.23 actual daily | 17 83% of assets perform better |
Based on monthly moving average BioSig Technologies, is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioSig Technologies, by adding it to a well-diversified portfolio.
BioSig Technologies, Fundamentals Growth
BioSig OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BioSig Technologies,, and BioSig Technologies, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioSig OTC Stock performance.
| Return On Equity | -59.77 | ||||
| Return On Asset | -4.48 | ||||
| Operating Margin | (227.43) % | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 14.12 M | ||||
| Price To Earning | (3.73) X | ||||
| Price To Book | 36.58 X | ||||
| Price To Sales | 90.04 X | ||||
| Revenue | 18 K | ||||
| EBITDA | (28.15 M) | ||||
| Cash And Equivalents | 887 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 452 K | ||||
| Debt To Equity | 0.45 % | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (17.31 M) | ||||
| Earnings Per Share | (0.86) X | ||||
| Total Asset | 1.8 M | ||||
| Retained Earnings | (245.01 M) | ||||
| Current Asset | 984.54 K | ||||
| Current Liabilities | 2.47 M | ||||
About BioSig Technologies, Performance
By examining BioSig Technologies,'s fundamental ratios, stakeholders can obtain critical insights into BioSig Technologies,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BioSig Technologies, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut. Biosig Technologies operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.Things to note about BioSig Technologies, performance evaluation
Checking the ongoing alerts about BioSig Technologies, for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BioSig Technologies, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioSig Technologies, is way too risky over 90 days horizon | |
| BioSig Technologies, may become a speculative penny stock | |
| BioSig Technologies, appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 18 K. Net Loss for the year was (28.69 M) with profit before overhead, payroll, taxes, and interest of 242 K. | |
| BioSig Technologies, Common currently holds about 887 K in cash with (17.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 18.0% of the company shares are held by company insiders |
- Analyzing BioSig Technologies,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioSig Technologies,'s stock is overvalued or undervalued compared to its peers.
- Examining BioSig Technologies,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioSig Technologies,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioSig Technologies,'s management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of BioSig Technologies,'s otc stock. These opinions can provide insight into BioSig Technologies,'s potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in BioSig OTC Stock
BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.